From GlobeNewswire: 2025-04-12 09:00:00

The Immunoassay Analyzers Market, valued at USD 7.55 billion in 2023, is projected to reach USD 10.16 billion by 2032, growing at a CAGR of 3.38%. Factors driving growth include increasing prevalence of chronic diseases and advancements in technology. The U.S. market is expected to reach USD 3.22 billion by 2032, with a CAGR of 3.02%.

In North America, strong government support and FDA clearances are driving the immunoassay analyzers market. Worldwide, the market is growing due to the COVID-19 pandemic, rising demand for accurate diagnostics, and increased healthcare spending. Key companies profiled in the report include Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers.

Consumables and Accessories dominated the market in 2023, with a 37.12% share, driven by repeat demand for reagents and kits. The ELISA segment is expected to experience the highest growth due to its sensitivity and cost-effectiveness. Infectious Disease Testing held the largest share in 2023, while the Endocrinology segment is expected to witness the highest growth in the coming years.

Hospitals dominated the market in 2023 with a 48.23% share, offering quick and precise diagnostic testing. Diagnostic Laboratories are expected to grow rapidly due to the increasing complexity of tests. North America led the market in 2023 with a 43.25% share, while Asia-Pacific is expected to witness the highest growth rate in the forecast period.

Overall, the immunoassay analyzers market is projected to witness significant growth driven by factors such as the increasing prevalence of chronic diseases, rising demand for accurate diagnostics, and advancements in technology. Major companies in the market include Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers. The global immunoassay analyzers market is expected to see high growth in emerging markets due to increased automation. Recent developments include Axis-Shield plc releasing an anti-CCP assay and Roche receiving CE Mark approval for its VENTANA FOLR1 RxDx Assay. The global prevalence of diabetes is rising, driving demand for diagnostic tools, especially in North America and Asia-Pacific.

Thermo Fisher Scientific launched the EXENT Solution after receiving IVDR Certification, offering an easy-to-implement system for clinical laboratories. The global prevalence of diabetes reached approximately 529 million cases in 2023, highlighting the growing demand for diagnostic tools like immunoassay analyzers. The Asia-Pacific region is expected to substantially increase immunoassay analyzer installations, supported by government investments in healthcare infrastructure.

The Asia-Pacific region is expected to substantially increase immunoassay analyzer installations, supported by government investments in healthcare infrastructure. North America witnessed a significant increase in prescriptions for immunoassay-based tests, driven by rising cases of chronic diseases and infectious outbreaks. Asia-Pacific saw a sharp rise in demand for immunoassay tests due to increasing healthcare awareness and improved access to diagnostics.



Read more at GlobeNewswire: Immunoassay Analyzers Market Size to Hit USD 10.16 Billion